Combining gene and immunotherapy for prostate cancer

Area of Science:

• Oncology
• Gene Therapy
• Cancer Research

Background:

• The nitroreductase (NR)/CB1954 enzyme prodrug system shows promise in preclinical and clinical prostate cancer studies.
• Co-expression of NR and murine granulocyte macrophage colony-stimulating factor (GM-CSF) with an adenoviral vector enhanced tumor cell killing in pancreatic and colorectal cancer models via immune-mediated mechanisms.

Purpose of the Study:

• To investigate if combining NR/CB1954 suicide gene therapy with GM-CSF cytokine stimulation could enhance tumor cell killing in prostate cancer using the TRAMP model.
• To determine the mechanism behind the enhanced therapeutic response.

Main Methods:

• Utilized a replication-deficient adenoviral vector to co-express NR and murine GM-CSF (mGM-CSF) under the control of the CMV immediate early promoter and an internal ribosome entry site (IRES).
• Administered NR/CB1954 suicide gene therapy combined with mGM-CSF cytokine stimulation in the TRAMP mouse model of prostate cancer.

Main Results:

• The combination of NR/CB1954 suicide gene therapy and mGM-CSF cytokine stimulation demonstrated an improved therapeutic response in the TRAMP model compared to either monotherapy.
• The enhanced response observed was likely mediated by non-immune mechanisms, as evidenced by the lack of a memory effect.

Conclusions:

• Combined suicide gene therapy (NR/CB1954) and cytokine gene therapy (mGM-CSF) offers a synergistic approach for enhanced prostate cancer treatment.
• The improved efficacy appears to be independent of immune-mediated mechanisms, suggesting a direct cytotoxic effect or other non-immune pathways are involved.